Pernix Commences Refinancing Transactions to Fortify Balance Sheet
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/29/2026
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- HF Sinclair plans to spin off lubricants unit, close Canadian refinery
- SoFi Technologies (SOFI) Tops Q2 EPS by 1c ; Offers Guidance
- Crude Inventory Fell 7.2 Million Barrels Last Week - EIA
- S&P 500 ends higher as investors await tech earnings
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
Pernix Therapeutics (PTX) Reports Prelim. Q2 Revenue of $33M-$35M
July 20, 2017 4:57 PM EDTPernix Therapeutics Holdings, Inc. (NASDAQ: PTX) today announced certain preliminary unaudited financial results for the second quarter ended June 30, 2017.
Second Quarter 2017 Preliminary Unaudited Financial Highlights:
Second quarter 2017 net revenues are expected to be between $33.0 million and $35.0 million, which would represent a decrease of between 5% and 10% versus second quarter 2016 net revenues of $36.7 million.Second quarter 2017 selling, general and administrative expense is expected to be between $18.0... More